Further, NCATS will catalyze collaborations between stakeholders emanating from siloed communities within and between discovery, development, and practice, investing them in a public-private partnership that is science-based, driving clinical development that enhances efficiencies and reduces risks associated with the development of the next generation of healthcare solutions.
Importantly, NCATS will contribute to producing the next generation of clinical and translational investigators. Equilibrating the balance between discovery and translation requires a cohort of multidisciplinary investigators with fluency in the lexicon and paradigms characterizing the laboratory and clinic, to enable integration of these broadly different domains. 4 Also, re-balancing entails a transition in professional culture that rewards team science. 5 This envisioned future will require the creation of a brand for clinical and translational science that attracts novice investigators into training programs, to produce the interdisciplinary teams which not only maintain the balance between basic and applied science but most appropriately, are capable of translating a discovery into therapeutic interventions with great promise for good. 4, 6, 7 The creators of NCATS identified clinical pharmacology as one foundational element essential to success along the discovery-application continuum. 8 
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